Biocorrx INC 10-K annual reports

BioCorRx Inc. reported a reduced net loss and a significant revenue increase in 2025, driven by a new acquisition and substantial grant funding, despite ongoing going concern doubts and internal control weaknesses.

BioCorRx Inc. reports its annual results for the fiscal year ended December 31, 2024, detailing financial performance, research and development activities, and strategic initiatives.

BioCorRx Inc. announces its 2023 financial results, highlighting a net loss but also securing a significant $11 million grant for the development of a methamphetamine use disorder treatment.